Navigation Links
PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
Date:12/21/2011

BOSTON, Dec. 21, 2011 /PRNewswire/ -- To help emerging and mid-size biopharmaceutical companies address an increasingly challenging regulatory and commercial environment, PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it is introducing a series of executive briefings with clinical operations and outsourcing leaders worldwide.  During these forums, PAREXEL will discuss how a spectrum of proven operating practices and relationship models can significantly reduce timelines and costs and streamline protocols and programs.

Through these educational briefings, designed for emerging and mid-size biopharmaceutical companies, PAREXEL senior project leaders and teams will discuss customized solutions that can assist companies in achieving their short- and long-term development and commercialization milestones. The teams will address key issues that may impact critical areas for emerging and mid-sized biopharmaceutical companies, including:

  • Optimizing patient recruitment strategy
  • Meeting "first patient in" timelines
  • Accessing real-time data
  • Achieving database lock timelines
  • Accelerating the speed of site recruitment
  • Implementing risk management and contingency planning approaches
  • "Deep collaboration with emerging and mid-size biopharmaceutical companies has been part of our DNA for nearly 30 years. We are committed to continuing to work with these clients to help them navigate the next stages of their businesses in the 'niche-buster' era, and in a challenging regulatory and commercial environment," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL. "Through a flexible and innovative approach, we create solutions that are the 'right fit' for every client. We're looking forward to bringing th
    '/>"/>

    SOURCE PAREXEL International Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. PAREXEL Closes the Acquisition of ClinPhone
    2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
    3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
    4. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
    5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
    6. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
    7. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
    8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
    9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
    10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
    11. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
    (Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
    (Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
    (Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
    Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
    ... researchers at the Swedish medical university Karolinska Institutet shows ... "bad" LDL cholesterol and thereby cause an inflammation that ... T cell receptors, the researchers have managed to inhibit ... presented online in the distinguished periodical Journal of ...
    ... discovered that simple peptides can organize into bi-layer membranes. ... pre-biotic Earth,s chemical inventory and the organizational scaffolding essential ... form the kind of membranes needed to create long-range ... of the paper recently published by the German Chemical ...
    ... Conference Call on Thursday, May 6, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA , and VANCOUVER , May 6 /PRNewswire-FirstCall/ - OncoGenex ... three months ended March 31, 2010 and reviewed the Company,s highlights for the first quarter ... Financial Results , , , ...
    Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Peptides may hold 'missing link' to life 2Peptides may hold 'missing link' to life 3OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6OncoGenex Reports First Quarter Financial Results 7OncoGenex Reports First Quarter Financial Results 8OncoGenex Reports First Quarter Financial Results 9
    (Date:8/28/2014)... PAUL (August 28, 2014) Researchers at the University ... facioscapulohumeral muscular dystrophy (FSHD) to be used for muscle ... of potential therapies for FSHD. , The research is ... Cell Reports . , There is no treatment for ... most common type of muscular dystrophy. FSHD is an ...
    (Date:8/28/2014)... that could positively impact the global battle ... thanks to researchers in Penn State,s College ... made from the seaweed-derived food ingredient carrageenan ... provides a woman-initiated, drug-delivery vehicle that can ... infections during unprotected heterosexual intercourse, the researchers ...
    (Date:8/28/2014)... 25 million kilometres of new roads will be built ... into Earth,s last wildernesses, where they bring an influx ... Now, an ambitious study has created a ,global roadmap, ... to balance the competing demands of development and environmental ... layer that estimates that natural importance of ecosystems and ...
    Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
    ... the European Medicines Agency (EMA) approved the modified adeno-associated ... for clinical use in the Western world. uniQure, a ... treatment of a rare inherited metabolic disease called lipoprotein ... out of one million people. The disease causes severe, ...
    ... 2013  Paris Air Show – Marvin Test Solutions ... provider of innovative test solutions for military and commercial ... the Paris Air Show in booth 3-C82. ... longer lifecycles, industry leaders are demanding efficient, feature-rich, specialized ...
    ... Kingdom, the Energy Department,s National Renewable Energy Laboratory (NREL), ... paper describing a novel cellulose-degrading enzyme from a marine ... the gribble. Gribbles are biologically intriguing because ... own enzymes instead of using symbiotic microbes to break ...
    Cached Biology News:No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Novel enzyme from tiny gribble could prove a boon for biofuels research 2
    ...
    ... Human IgG Fd. ELISA Specificity: (4) ,human IgG subclass 1 ... 100% ,human IgG subclass 3 100% ,human IgG ... ... 0.04% ,human IgG Fab ...
    Human VEGF R2 (KDR) MAb (Clone 89106)...
    Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
    Biology Products: